Ireland· IE-PA-PA1026/001/001
Neupogen 30 MU (0.3 mg/ml) Solution for injection filgrastim
A filgrastim product containing filgrastim, registered in Ireland by Amgen Europe B.V.,. The same ATC class is registered in 17 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Filgrastim is registered in 17 of 19 countries.
Countries holding a registration under ATC L03AA02 (filgrastim), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 10 of them publish a price we can compare per daily dose
Filgrastim · ATC L03AA02
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- Filgrastim
- Manufacturer
- Amgen Europe B.V.,
- Country
- Ireland (IE)
- ATC code
- L03AA02
- ATC class
- Filgrastim
- Defined daily dose
- 0.35 mg, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA1026/001/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
191 interactions on record for filgrastim.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Filgrastim · interactions on record
191 records
- 2 severe
- 189 moderate
Most severe, free to view
- CladribineL01BB04severe
- CyclophosphamideL01AA01moderate
- ChlorambucilL01AA02moderate
- MelphalanL01AA03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Filgrastim in 18 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesNEUPOGENAmgen, Inc
- CzechiaACCOFILAccord Healthcare S.L.U., Barcelona
- FinlandAccofilAccord Healthcare S.L.U.
- SpainACCOFIL 12 MU/0,2 ML SOLUCION INYECTABLE Y PARA PERFUSION EN JERINGA PRECARGADAAccord Healthcare S.L.U.
- BelgiumAccofil 12 10*6 U/0.2 mlAccord Healthcare
- PolandAccofilAccord Healthcare S.L.U.
- NetherlandsAccofil 30MU/0,5ml solution for injection or infusionAccord Healthcare S.L.U.
- SwedenAccofil 12 ME/0,2 ml Injektions- / infusionsvätska, lösning i förfylld sprutaAccord Healthcare S.L.U.
Authorised across Europe · EMA
The same active substance is authorised in 14 EEA countries. Names it is sold under:
- Belgium · Neupogen
- Germany · Neupogen
- Spain · Neupogen
- France · Neupogen
- United Kingdom (Northern Ireland) · Neupogen, Neupogen Singleject
- Iceland · Accofil, Filgrastim Hexal
- Italy · Granulokine
- Liechtenstein · Accofil, Filgrastim Hexal
- Luxembourg · Neupogen
- Netherlands · Neupogen, Neupogen Singleject
- Norway · Accofil, Filgrastim Hexal
- Poland · Neupogen
- Sweden · Neupogen
- Slovenia · Neupogen
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/87ef5085-c00a-4e74-8d97-696fc6360a94 GET /v1/drugs/87ef5085-c00a-4e74-8d97-696fc6360a94?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"routes": [
"Intravenous use",
"Subcutaneous use"
],
"source": "hpra",
"atc_all": [
"L03AA",
"L03AA02"
],
"strength": null,
"pa_number": "PA1026/001/001",
"substances": [
"Filgrastim"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Marketed",
"authorised_at": "11/06/1991",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about filgrastim.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.